Form 8-K · Current report
Moderna 8-K, filed Jul 31, 2026
- Filed
- CIK
- 0001682852
- Accession no.
- 0001682852-26-000147
Summary
Moderna reported second-quarter 2026 total revenue of $145 million and a GAAP net loss of $0.8 billion, reiterated its plan for up to 10% revenue growth in 2026, and improved its full-year operating expense and year-end cash outlook to $4.7–5.2 billion. The company said its norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at a Phase 3 interim analysis and it is preparing to enroll an additional cohort, while it anticipates a potential August 5 approval decision for its seasonal influenza vaccine candidate mFLUSIVA.
Key points
- Second-quarter 2026 revenue was $145 million versus $142 million a year earlier, with a net loss of $0.8 billion, or $(1.97) per share.
- Moderna's Phase 3 safety and efficacy study of norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at an interim analysis; the trial remains blinded and the company is preparing to enroll an additional cohort.
- Five-year Phase 2b adjuvant melanoma data presented at ASCO showed intismeran autogene (mRNA-4157) plus KEYTRUDA reduced the risk of recurrence or death by 49% compared with KEYTRUDA alone.
- Moderna signed a joint procurement contract with the European Commission on behalf of six countries for up to 24 million doses of mRESVIA, and appointed Ester Banque chief commercial officer and former Biogen CFO Michael McDonnell to its board.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 31, 2026, Moderna, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.